adenosine monophosphate has been researched along with Acute Coronary Syndrome in 56 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 12 (21.43) | 29.6817 |
| 2010's | 37 (66.07) | 24.3611 |
| 2020's | 7 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Berti, S; Bolognese, L; Calabrò, P; Capranzano, P; Cernetti, C; Chirillo, F; Cirillo, P; Contarini, M; De Luca, L; Di Mario, C; Ferlini, M; Lanzilotti, V; Maffeo, D; Mauro, C; Menichelli, M; Menozzi, A; Muraglia, S; Musumeci, G; Nicolini, E; Pepe, M; Rolfo, C; Rossini, R; Scherillo, M; Talanas, G; Tarantini, G; Tomai, F; Trani, C; Versaci, F | 1 |
| Baber, U | 1 |
| Alexopoulos, D; Lianos, I; Mpahara, A; Varlamos, C | 1 |
| Di Tano, G; Galeazzi, G; Loffi, M; Passamonti, E; Pedroni, P | 1 |
| Ben-Dor, I; Bernardo, NL; Case, BC; Chezar-Azerrad, C; Forrestal, BJ; Garcia-Garcia, HM; Hashim, H; Medranda, GA; Satler, LF; Shea, C; Waksman, R; Yerasi, C; Zhang, C | 1 |
| Biondi-Zoccai, G; Carulli, E; Cirillo, P; D'Alessandro, P; Ercolano, V; Esposito, G; Favale, S; Forleo, C; Giordano, A; Larosa, C; Moscarelli, M; Nestola, PL; Palmiotto, AI; Pepe, M | 1 |
| Beavers, CJ; Dobesh, PP; Effoe, SA | 1 |
| Angiolillo, DJ; Bhatt, DL; Capodanno, D; De Luca, L; Steg, PG | 1 |
| Bhatt, DL; Borst, O; Droppa, M; Gawaz, M; Geisler, T; Müller, K; Rath, D | 1 |
| Droppa, M; Geisler, T | 1 |
| Calnan, MW; Crawford, AN | 1 |
| Desai, R; Doshi, R; Jain, A; Kansara, T; Majmundar, M; Mithawala, P; Shah, P | 1 |
| Bhatt, DL; de Waha-Thiele, S; Desch, S; Droppa, M; Fuernau, G; Gawaz, M; Geisler, T; Hack, L; Jaffer, FA; Ouarrak, T; Qamar, A; Rath, D; Roberts, RJ; Schneider, S; Singh, A; Szumita, PM; Thiele, H; Vaduganathan, M; Venkateswaran, RV; Zeymer, U | 1 |
| Bhatt, DL; Gibson, CM; Harrington, RA; Leonardi, S; Mahaffey, KW; Neely, ML; Stone, GW; Tricoci, P; Truffa, AA; White, HD; Wilson, M | 1 |
| Mills, NL; Newby, DE; Shah, AS | 1 |
| Giugliano, RP; Shimada, YJ | 1 |
| Manoukian, SV; Voeltz, MD | 1 |
| Aylward, PE; Sinhal, AR | 1 |
| Bhatt, DL; Day, JR; French, WJ; Gibson, CM; Gogia, HS; Gruberg, L; Hamm, CW; Harrington, RA; Iwaoka, RS; Leonardi, S; Liu, T; Mahaffey, KW; Skerjanec, S; Steg, PG; Stone, GW; Stuckey, TD; White, HD | 1 |
| Angiolillo, DJ; Cho, JR; Franchi, F; Muñiz-Lozano, A; Rollini, F | 1 |
| Fan, JY; Jin, C; Meng, J; Tang, XF; Yang, YJ; Yuan, JQ | 1 |
| Sabouret, P; Taiel-Sartral, M | 1 |
| Dobesh, PP; Oestreich, JH | 1 |
| Bonadei, I; D'Aloia, A; Metra, M; Raddino, R; Sciatti, E; Vizzardi, E | 1 |
| Anderson, JL; Bates, ER; Bode, C; Granger, CB; Huber, K; Kristensen, SD; Lopez Sendon, JL; Ohman, EM; Steg, PG; Tubaro, M; Valgimigli, M; Wallentin, L | 1 |
| Traynor, K | 1 |
| Angiolillo, DJ; Capodanno, D | 1 |
| Abnousi, F; Bhatt, DL; Gibson, CM; Hamm, CW; Harrington, RA; Leonardi, S; Lopes, RD; Mahaffey, KW; Mangum, S; Menozzi, A; Prats, J; Price, MJ; Steg, PG; Stone, GW; Todd, M; White, HD; Wilson, M | 1 |
| Alboji, A; Droppa, M; Gawaz, M; Geisler, T; Jeong, YH; Müller, KAL; Rath, D; Spahn, P; Straub, A; Takhgiriev, K | 1 |
| Abnousi, F; Abtan, J; Bhatt, DL; Deliargyris, EN; Gibson, CM; Hamm, CW; Harrington, RA; Mahaffey, KW; Prats, J; Price, MJ; Steg, PG; Stone, GW; White, HD | 1 |
| Adamska, U; Adamski, P; Koziński, M; Kubica, J; Ostrowska, M | 1 |
| Bhatt, DL; Fuster, V; Gersh, BJ; Lennon, RJ; Narula, J; Rihal, CS; Singh, M; Stone, GW | 1 |
| Barker, CM; Price, MJ | 1 |
| Angiolillo, DJ; Guzman, LA | 1 |
| Moliterno, DJ | 1 |
| Angiolillo, DJ; Bhatt, DL; Gurbel, PA; Jennings, LK | 1 |
| Norgard, NB | 1 |
| Angiolillo, DJ; Ferreiro, JL; Ueno, M | 2 |
| Franchini, M; Mannucci, PM | 1 |
| Amine, M; Angiolillo, DJ; Becker, RC; Bhatt, DL; Chew, DP; French, WJ; Gibson, CM; Goodman, SG; Harrington, RA; Kleiman, NS; Leisch, F; Lincoff, AM; Mahaffey, KW; McNulty, S; Montalescot, G; Parikh, KH; Pollack, CV; Skerjanec, S; Stone, GW; White, HD | 1 |
| Kastrati, A; Ndrepepa, G | 1 |
| Arneja, J; Bhatt, DL; Chew, DP; Cura, F; Gibson, CM; Goodman, SG; Harrington, RA; Jafar, MZ; Kleiman, NS; Lincoff, AM; Mahaffey, KW; Manoukian, SV; Manukov, I; McNulty, S; Montalescot, G; Pollack, CV; Skerjanec, S; Stone, GW; Tousek, F; White, HD; Widimsky, P | 1 |
| Banach, M; Hannam, S; Kowalczyk, M; Mikhailidis, DP; Rysz, J | 1 |
| del Río, A; Heras, M | 1 |
| Faxon, DP | 1 |
| Lee, KL | 1 |
| Frey, N; Ivandic, B | 1 |
| Ağırbaşlı, M; Cinçin, A; Güvenç, H | 1 |
| Cattaneo, GJ; Cattaneo, M; Podda, GM | 1 |
| Moliterno, DJ; Rajan, L | 1 |
| Böhm, M; Schirmer, SH | 1 |
| Caglayan, E; Er, F; Erdmann, E; Gassanov, N | 1 |
| Angiolillo, DJ; Brtko, M; Cannon, L; Chandna, H; Dyke, C; Firstenberg, MS; Hutyra, M; Liu, T; Manoukian, SV; Montalescot, G; Prats, J; Price, MJ; Ramaiah, C; Topol, EJ; Tummala, PE; Voeltz, MD; Welsby, IJ | 1 |
| Contractor, H; Ruparelia, N | 1 |
| Barn, K; Steinhubl, SR | 1 |
32 review(s) available for adenosine monophosphate and Acute Coronary Syndrome
| Article | Year |
|---|---|
P2Y12 inhibitors for the treatment of acute coronary syndrome patients undergoing percutaneous coronary intervention: current understanding and outcomes.
Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Administration, Intravenous; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; ST Elevation Myocardial Infarction; Ticagrelor | 2019 |
Cangrelor: Clinical Data, Contemporary Use, and Future Perspectives.
Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Animals; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Risk Assessment; Risk Factors; Thrombosis; Treatment Outcome | 2021 |
What is the Role of Cangrelor in Patients Undergoing PCI?
Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Administration, Intravenous; Coronary Artery Disease; Coronary Thrombosis; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Risk Factors; Treatment Outcome | 2018 |
Meta-Analysis of the Role of Cangrelor for Patients Undergoing Percutaneous Coronary Intervention.
Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Global Health; Humans; Percutaneous Coronary Intervention; Preoperative Care; Purinergic P2Y Receptor Antagonists; Survival Rate | 2019 |
Emerging antithrombotic drugs for acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Fibrinolytic Agents; Humans; Lactones; Morpholines; Platelet Aggregation Inhibitors; Pyridines; Rivaroxaban; Thiophenes | 2013 |
New antiplatelet agents and the role of platelet function testing in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Blood Platelets; Clopidogrel; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2013 |
Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data.
Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Aged; Cause of Death; Coronary Disease; Double-Blind Method; Female; Graft Occlusion, Vascular; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Myocardial Ischemia; Myocardial Revascularization; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Stents; Treatment Outcome | 2013 |
Cangrelor: a review on pharmacology and clinical trial development.
Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Animals; Aspirin; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists | 2013 |
Impact of new oral or intravenous P2Y12 inhibitors and clopidogrel on major ischemic and bleeding events in patients with coronary artery disease: a meta-analysis of randomized trials.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Administration, Oral; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Fibrinolytic Agents; Hemorrhage; Humans; Injections, Intravenous; Multicenter Studies as Topic; Myocardial Infarction; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Quinazolinones; Randomized Controlled Trials as Topic; Stents; Stroke; Sulfonamides; Thiophenes; Thrombolytic Therapy; Ticagrelor; Ticlopidine | 2014 |
New antiplatelet agents in the treatment of acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Clinical Trials as Topic; Clopidogrel; Combined Modality Therapy; Coronary Artery Bypass; Coronary Thrombosis; Diabetes Complications; Hemorrhage; Humans; Multicenter Studies as Topic; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Precision Medicine; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Receptors, Purinergic P2Y12; Renal Insufficiency; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2014 |
New frontiers in the management of acute coronary syndromes: cangrelor and elinogrel.
Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Hemorrhage; Humans; Patents as Topic; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Quinazolinones; Sulfonamides | 2014 |
Antiplatelet and anticoagulation agents in acute coronary syndromes: what is the current status and what does the future hold?
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Anticoagulants; Aspirin; Drug Therapy, Combination; Enoxaparin; Eptifibatide; Fondaparinux; Heparin; Hirudins; Humans; Lactones; Peptide Fragments; Peptides; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Polysaccharides; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Pyridines; Receptors, Thrombin; Recombinant Proteins; Thiophenes; Ticagrelor; Tirofiban; Tyrosine; Warfarin | 2014 |
Reviewing the controversy surrounding pre-treatment with P2Y12 inhibitors in acute coronary syndrome patients.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Clopidogrel; Coronary Artery Disease; Humans; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine | 2016 |
New directions for pharmacotherapy in the treatment of acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Antibodies, Monoclonal; Anticholesteremic Agents; Clinical Trials as Topic; Drug Discovery; Ezetimibe; Humans; PCSK9 Inhibitors; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Thrombosis; Treatment Outcome | 2016 |
Antithrombotic Approaches in Acute Coronary Syndromes: Optimizing Benefit vs Bleeding Risks.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Anticoagulants; Antithrombins; Clinical Trials as Topic; Cytochrome P-450 CYP2C19; Drug Therapy, Combination; Factor Xa Inhibitors; Fibrinolytic Agents; Genotype; Hemorrhage; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Polymorphism, Genetic; Practice Guidelines as Topic; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor | 2016 |
Clinical overview of promising nonthienopyridine antiplatelet agents.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Angioplasty, Balloon, Coronary; Aspirin; Clinical Trials as Topic; Coronary Disease; Drug Therapy, Combination; Humans; Lactones; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Pyridines; Receptors, Thrombin; Ticagrelor | 2008 |
Advances in antiplatelet therapy for ACS and PCI.
Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Angina, Unstable; Aspirin; Blood Platelets; Cardiac Catheterization; Fibrinolytic Agents; Humans; Lactones; Myocardial Infarction; Platelet Activation; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Pyridines; Treatment Outcome | 2008 |
Advances in antiplatelet therapy: agents in clinical development.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Angioplasty, Balloon, Coronary; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Signal Transduction; Thiophenes; Ticagrelor; Treatment Outcome | 2009 |
Cangrelor: a novel P2Y12 receptor antagonist.
Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Animals; Clinical Trials as Topic; Coronary Thrombosis; Drug Evaluation, Preclinical; Humans; Molecular Structure; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12 | 2009 |
Cangrelor: a review on its mechanism of action and clinical development.
Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Animals; Clinical Trials as Topic; Humans; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12 | 2009 |
New antiplatelet agents: why they are needed.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Humans; Lactones; Naphthalenes; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prodrugs; Propionates; Pyridines; Thiophenes; Ticagrelor | 2009 |
Ticagrelor--a new platelet aggregation inhibitor in patients with acute coronary syndromes. An improvement of other inhibitors?
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Biotransformation; Clinical Trials as Topic; Clopidogrel; Hemorrhage; Humans; Lactones; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Pyridines; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Thiophenes; Ticagrelor; Ticlopidine | 2009 |
Update on antiplatelet therapy in acute coronary syndromes: what do new drugs bring into clinical practice?
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Diphosphate; Adenosine Monophosphate; Clopidogrel; Humans; Lactones; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Pyridines; Thiophenes; Ticagrelor; Ticlopidine | 2009 |
Update on the clinical development of cangrelor.
Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Angioplasty, Balloon, Coronary; Animals; Clinical Trials as Topic; Humans; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12 | 2010 |
[New approaches and indications for the analysis of platelet function in cardiology].
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Interactions; Hemorrhage; Humans; Piperazines; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine | 2011 |
[Novel agents in antiplatelet therapy].
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Aspirin; Clopidogrel; Humans; Lactones; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Pyridines; Receptors, Thrombin; Thiophenes; Ticagrelor; Ticlopidine | 2010 |
[Recent advances on the studies of the platelet's inhibition and aggregation. State of the art of new P2Y12 antagonists].
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Catheter Ablation; Clinical Trials as Topic; Clopidogrel; Coronary Artery Bypass; Humans; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticagrelor; Ticlopidine | 2011 |
Beyond aspirin and clopidogrel: is there a need for additional antiplatelet therapy in ACS?
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Aspirin; Cilostazol; Clopidogrel; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Quinazolinones; Receptors, Purinergic P2Y12; Sulfonamides; Tetrazoles; Thiophenes; Ticagrelor; Ticlopidine | 2011 |
[Update on anti-platelet therapy].
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Humans; Piperazines; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Precision Medicine; Thiophenes; Thrombolytic Therapy; Ticagrelor | 2011 |
[ADP receptor blockers: new insights in the therapy and prophylaxis of ischemic heart disease].
Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Combined Modality Therapy; Humans; Myocardial Ischemia; Platelet Aggregation Inhibitors; Pyridines; Receptors, Purinergic P2; Stents; Ticlopidine | 2011 |
Advances in antiplatelet therapy for acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Aspirin; Clopidogrel; Emergency Treatment; Female; Humans; Male; Patient Selection; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Quinazolinones; Sulfonamides; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2012 |
A brief review of the past and future of platelet P2Y12 antagonist.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Clopidogrel; Coronary Artery Disease; Humans; Myocardial Infarction; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Quinazolinones; Stents; Sulfonamides; Thiophenes; Thrombosis; Ticagrelor; Ticlopidine | 2012 |
7 trial(s) available for adenosine monophosphate and Acute Coronary Syndrome
| Article | Year |
|---|---|
Cangrelor in cardiogenic shock and after cardiopulmonary resuscitation: A global, multicenter, matched pair analysis with oral P2Y
Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Administration, Oral; Aged; Combined Modality Therapy; Female; Humans; Male; Matched-Pair Analysis; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Shock, Cardiogenic | 2019 |
Cangrelor in patients undergoing cardiac surgery: the BRIDGE study.
Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Coronary Artery Bypass; Double-Blind Method; Follow-Up Studies; Humans; Platelet Aggregation Inhibitors; Prospective Studies; Purinergic P2Y Receptor Antagonists; Time Factors; Treatment Outcome | 2013 |
Implications of different criteria for percutaneous coronary intervention-related myocardial infarction on study results of three large phase III clinical trials: The CHAMPION experience.
Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Aged; Dose-Response Relationship, Drug; Double-Blind Method; Europe; Female; Humans; Incidence; Male; Middle Aged; Myocardial Infarction; New Zealand; Odds Ratio; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticlopidine; Treatment Outcome; United States | 2018 |
Efficacy and Safety of Cangrelor in Preventing Periprocedural Complications in Patients With Stable Angina and Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: The CHAMPION PHOENIX Trial.
Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Aged; Angina, Stable; Chi-Square Distribution; Clopidogrel; Coronary Thrombosis; Double-Blind Method; Female; Hemorrhage; Humans; Logistic Models; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Risk Factors; Ticlopidine; Time Factors; Treatment Outcome | 2016 |
Platelet inhibition with cangrelor in patients undergoing PCI.
Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Combined Modality Therapy; Double-Blind Method; Female; Hemorrhage; Humans; Infusions, Intravenous; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Retreatment; Ticlopidine; Treatment Failure | 2009 |
Intravenous platelet blockade with cangrelor during PCI.
Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Aged; Angioplasty, Balloon, Coronary; Combined Modality Therapy; Coronary Thrombosis; Double-Blind Method; Female; Hemorrhage; Humans; Infusions, Intravenous; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Retreatment; Stents; Treatment Outcome | 2009 |
Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial.
Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Adult; Aged; Aged, 80 and over; Blood Loss, Surgical; Coronary Artery Bypass; Coronary Artery Disease; Double-Blind Method; Female; Humans; Male; Middle Aged; Platelet Activation; Platelet Aggregation Inhibitors; Postoperative Hemorrhage; Purinergic P2Y Receptor Antagonists; Stents; Thienopyridines; Thrombosis | 2012 |
17 other study(ies) available for adenosine monophosphate and Acute Coronary Syndrome
| Article | Year |
|---|---|
Use of cangrelor in patients with acute coronary syndromes undergoing percutaneous coronary intervention: Study design and interim analysis of the ARCANGELO study.
Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Adult; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; Purinergic P2Y Receptor Antagonists; Treatment Outcome | 2022 |
Switching Between Intravenous and Oral P2Y
Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Administration, Intravenous; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Ticagrelor; Treatment Outcome | 2023 |
Who was the culprit? Non-ST-elevation acute coronary syndrome treated with percutaneous coronary intervention and cangrelor infusion.
Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Aged; Combined Modality Therapy; Electrocardiography; Female; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors | 2019 |
Cangrelor vs. glycoprotein IIb/IIIa inhibitors during percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Female; Gastrointestinal Hemorrhage; Hematocrit; Hemorrhage; Humans; Length of Stay; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Purinergic P2Y Receptor Antagonists; Retrospective Studies; ST Elevation Myocardial Infarction | 2021 |
Clinical use of cangrelor: a real-world multicenter experience from South Italy.
Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Treatment Outcome | 2022 |
Selatogrel: A Novel Subcutaneous P2Y12 Inhibitor.
Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Humans; Organophosphonates; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Pyrimidines | 2022 |
Impact of Intravenous P2Y12-Receptor Inhibition with Cangrelor in Patients Presenting with Acute Coronary Syndrome and Cardiogenic Shock - a Case Series.
Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Administration, Intravenous; Aged; Cardiotonic Agents; Female; Gene Expression; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y; Shock, Cardiogenic; Survival Analysis | 2017 |
A Case Report of Cangrelor Bridge Therapy for a Diagnostic Bronchoscopy With Biopsy.
Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Aged; Aspirin; Biopsy; Bronchoscopy; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; Dual Anti-Platelet Therapy; Female; Hemorrhage; Humans; Perioperative Care; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor | 2020 |
A novel approach to systematically implement the universal definition of myocardial infarction: insights from the CHAMPION PLATFORM trial.
Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Aged; Biomarkers; Creatine Kinase, MB Form; Female; Humans; Logistic Models; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Risk Assessment; Sensitivity and Specificity; Troponin | 2013 |
Periprocedural type IVa myocardial infarction and the importance of platelet inhibition.
Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Creatine Kinase, MB Form; Female; Humans; Male; Myocardial Infarction; Percutaneous Coronary Intervention; Purinergic P2Y Receptor Antagonists; Troponin | 2013 |
Cangrelor for treatment during percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Aspirin; Clinical Trials as Topic; Coronary Thrombosis; Drug Interactions; Drug Therapy, Combination; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Postoperative Complications; Purinergic P2Y Receptor Antagonists; Stents | 2014 |
Cangrelor approved for use during coronary angioplasty.
Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Angioplasty, Balloon, Coronary; Coronary Thrombosis; Drug Approval; Humans; Infusions, Intravenous; Intraoperative Care; Platelet Aggregation Inhibitors; United States; United States Food and Drug Administration | 2015 |
Periprocedural platelet inhibition with cangrelor in P2Y
Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Administration, Intravenous; Aged; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Perioperative Care; Platelet Aggregation; Platelet Function Tests; Purinergic P2Y Receptor Antagonists; Treatment Outcome | 2016 |
Antiplatelet therapy in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine | 2008 |
Cangrelor - a champion lost in translation?
Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Angioplasty, Balloon, Coronary; Combined Modality Therapy; Humans; Platelet Aggregation Inhibitors; Research Design; Treatment Failure | 2009 |
Antiplatelet therapy: cangrelor for ACS-lessons from the CHAMPION trials.
Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Angioplasty, Balloon, Coronary; Blood Platelets; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Randomized Controlled Trials as Topic; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Thrombosis; Ticlopidine; Treatment Outcome | 2010 |
Testing a new approach for rapid and reversible platelet inhibition during percutaneous coronary intervention among patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Aged; Angioplasty, Balloon, Coronary; Combined Modality Therapy; Coronary Thrombosis; Double-Blind Method; Female; Hemorrhage; Humans; Infusions, Intravenous; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Retreatment; Stents; Treatment Outcome | 2010 |